GT
GSK icon

Glenmede Trust’s GSK GSK Stock Holding History

Glenmede Trust’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.6M Sell
47,138
-7,530
-14% -$408K 0.01% 529
2025
Q4 		$2.68M Buy
+54,668
New +$2.55M 0.01% 524
2025
Q1 		$2.13M Buy
54,865
+972
+2% +$35.6K 0.01% 542
2024
Q4 		$1.82M Sell
53,893
-11,984
-18% -$431K 0.01% 563
2024
Q3 		$2.69M Sell
65,877
-5,633
-8% -$230K 0.01% 521
2024
Q2 		$2.75M Buy
71,510
+1,928
+3% +$81.1K 0.01% 501
2024
Q1 		$2.98M Buy
69,582
+134
+0.2% +$5.53K 0.02% 508
2023
Q4 		$2.57M Buy
69,448
+4,735
+7% +$170K 0.01% 505
2023
Q3 		$2.35M Sell
64,713
-1,480
-2% -$52.5K 0.01% 490
2023
Q2 		$2.36M Hold
66,193
– – 0.01% 489
2023
Q1 		$2.36M Buy
66,193
+558
+0.9% +$19.5K 0.01% 491
2022
Q4 		$2.31M Buy
65,635
+1,255
+2% +$41.8K 0.01% 497
2022
Q3 		$1.89M Sell
64,380
-2,634
-4% -$99.8K 0.01% 513
2022
Q2 		$3.65M Buy
67,014
+564
+0.8% +$31.1K 0.02% 439
2022
Q1 		$3.62M Sell
66,450
-1,987
-3% -$108K 0.02% 465
2021
Q4 		$3.77M Sell
68,437
-9,425
-12% -$490K 0.02% 464
2021
Q3 		$3.72M Sell
77,862
-732
-0.9% -$36.8K 0.02% 449
2021
Q2 		$3.91M Sell
78,594
-6,583
-8% -$316K 0.02% 432
2021
Q1 		$3.8M Buy
85,177
+4,542
+6% +$206K 0.02% 425
2020
Q4 		$3.71M Sell
80,635
-32,348
-29% -$1.49M 0.02% 436
2020
Q3 		$5.31M Sell
112,983
-10,066
-8% -$504K 0.03% 379
2020
Q2 		$6.27M Sell
123,049
-62,101
-34% -$3.19M 0.04% 355
2020
Q1 		$10.9M Hold
185,150
– – 0.05% 355
2019
Q4 		$10.9M Sell
185,150
-5,226
-3% -$291K 0.05% 355
2019
Q3 		$10.2K Buy
190,376
+841
+0.4% +$43.3K 0.05% 353
2019
Q2 		$9.48K Sell
189,535
-1,331
-0.7% -$66.8K 0.04% 379
2019
Q1 		$9.97K Buy
190,866
+33,320
+21% +$1.66M 0.05% 371
2018
Q4 		$7.52K Buy
157,546
+58,508
+59% +$2.88M 0.04% 384
2018
Q3 		$4.97M Sell
99,038
-11,284
-10% -$573K 0.02% 488
2018
Q2 		$5.56M Sell
110,322
-2,832
-3% -$143K 0.02% 447
2018
Q1 		$5.02M Hold
113,154
– – 0.02% 485
2017
Q4 		$5.02M Sell
113,154
-488
-0.4% -$22.5K 0.02% 485
2017
Q3 		$5.77M Sell
113,642
-139,440
-55% -$7.07M 0.03% 456
2017
Q2 		$13.3M Hold
253,082
– – 0.06% 333
2017
Q1 		$13.3M Sell
253,082
-11,392
-4% -$578K 0.06% 333
2016
Q4 		$12.7M Sell
264,474
-1,517
-0.6% -$74.9K 0.07% 336
2016
Q3 		$14.3M Buy
265,991
+7,125
+3% +$391K 0.08% 325
2016
Q2 		$14M Buy
258,866
+21,251
+9% +$1.12M 0.09% 318
2016
Q1 		$12M Buy
237,615
+117,175
+97% +$5.84M 0.08% 324
2015
Q4 		$6.07M Buy
120,440
+1,890
+2% +$96.3K 0.04% 396
2015
Q3 		$5.7M Buy
118,550
+28
+0% +$1.46K 0.04% 390
2015
Q2 		$6.17M Sell
118,522
-22,164
-16% -$1.25M 0.04% 395
2015
Q1 		$8.11M Sell
140,686
-6,375
-4% -$365K 0.06% 382
2014
Q4 		$7.86M Buy
147,061
+17,107
+13% +$957K 0.06% 373
2014
Q3 		$7.47M Sell
129,954
-8,208
-6% -$503K 0.07% 357
2014
Q2 		$9.23M Sell
138,162
-10,282
-7% -$696K 0.08% 324
2014
Q1 		$9.91M Sell
148,444
-2,923
-2% -$198K 0.09% 296
2013
Q4 		$10.1M Buy
151,367
+2,104
+1% +$136K 0.1% 268
2013
Q3 		$9.36M Sell
149,263
-3,183
-2% -$205K 0.11% 241
2013
Q2 		$9.52M Buy
+152,446
New +$9.68M 0.12% 183

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Glenmede Trust's GSK Position: Q1 2026 in Review

Glenmede Trust reduced its GSK (GSK) stake by 14% in Q1 2026, selling an estimated $408K and leaving 47,138 shares worth $2.6M. The position accounts for 0.01% of the portfolio, ranked #529.

Glenmede Trust first reported a position in GSK in Q2 2013 and has held it in 50 quarters since. The position peaked at $14.3M in Q3 2016. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

  • Glenmede Trust held 47,138 shares of GSK worth $2.6M as of Q1 2026.
  • Glenmede Trust sold 7,530 GSK shares in Q1 2026, an estimated $408K.
  • GSK made up 0.01% of Glenmede Trust's portfolio in Q1 2026, its #529 holding.
  • Glenmede Trust first reported a position in GSK in Q2 2013 and has held it in 50 quarters since.
  • Glenmede Trust's GSK position peaked at $14.3M in Q3 2016.
  • 1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Glenmede Trust's 13F filing for Q1 2026, filed 26 May 2026.